Get the Stockscreener App
12.79
0.95%
0.12
After Hours:
12.70
-0.09
-0.70%
Phathom Pharmaceuticals Inc stock is traded at $12.79, with a volume of 501.71K.
It is up +0.95% in the last 24 hours and up +23.34% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$12.67
Open:
$12.95
24h Volume:
501.71K
Relative Volume:
0.46
Market Cap:
$1.02B
Revenue:
$175.11M
Net Income/Loss:
$-221.25M
P/E Ratio:
-4.1914
EPS:
-3.0515
Net Cash Flow:
$-167.00M
1W Performance:
+8.30%
1M Performance:
+23.34%
6M Performance:
-4.91%
1Y Performance:
+168.13%
1-Day Range:
$12.69
$13.03
1-Week Range:
$11.59
$13.19
52-Week Range:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
12.79 | 1.01B | 175.11M | -221.25M | -167.00M | -3.0515 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-12-25 | Initiated | Raymond James | Strong Buy |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Responsive Playbooks and the PHAT Inflection - Stock Traders Daily
Aug Highlights: Is Phathom Pharmaceuticals Inc a cyclical or defensive stock2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
[ARS] Phathom Pharmaceuticals, Inc. SEC Filing - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) sets 2026 virtual meeting, director elections and say-on-pay vote - Stock Titan
Quarterly Recap: How correlated is Phathom Pharmaceuticals Inc to the S P5002026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Portfolio Recap: Is Phathom Pharmaceuticals Inc a cyclical or defensive stockQuarterly Profit Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
PHAT Technical Analysis & Stock Price Forecast - Intellectia AI
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
Portfolio Recap: What are the risks of holding Phathom Pharmaceuticals IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Phathom Pharmaceuticals Inc (PHAT) Stock News & Articles - 247wallst.com
Barclays upgrades Phathom Pharmaceuticals (PHAT) - MSN
Phathom upgraded at Barclays following pullback, Voquezna optimism ) - Seeking Alpha
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade - MarketBeat
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - Benzinga
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
Barclays Upgrades Phathom Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $18 From $16 - MarketScreener
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook - investing.com
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Weekly Recap: Does Phathom Pharmaceuticals Inc offer margin of safetyTrade Performance Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Whats Phathom Pharmaceuticals Incs historical return2026 Market WrapUp & Weekly High Return Forecasts - baoquankhu1.vn
Analyst Calls: Does Phathom Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Safe Entry Momentum Tips - baoquankhu1.vn
Millennium (PHAT) group discloses 4.18M shares (5.3%) in Phathom (PHAT) - Stock Titan
Phathom Pharmaceuticals (PHAT) director gifts 80,000 shares to trust - Stock Titan
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - The Globe and Mail
Phathom Pharmaceuticals (PHAT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision Trading with Phathom Pharmaceuticals Inc. (PHAT) Risk Zones - Stock Traders Daily
Certain Performance Stock Units of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth - MSN
GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Tech Rally: Does Phathom Pharmaceuticals Inc have strong fundamentalsQuarterly Trade Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
PHAT Should I Buy - Intellectia AI
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up - TipRanks
PHAT Technical Analysis & ETF Price Forecast - Intellectia AI
Phathom Pharmaceuticals Hits Day Low of $12.32 Amid Price Pressure - Markets Mojo
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):